Certara, Inc. (NASDAQ:CERT) Receives Average Rating of "Moderate Buy" from Analysts

Certara, Inc. (NASDAQ:CERT - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $15.29.

A number of research firms have issued reports on CERT. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. KeyCorp reduced their price objective on Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Robert W. Baird boosted their target price on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Morgan Stanley assumed coverage on shares of Certara in a research note on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 target price for the company. Finally, Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th.

Certara Price Performance

Shares of Certara stock opened at $11.09 on Friday. Certara has a 1-year low of $8.64 and a 1-year high of $16.18. The firm has a fifty day simple moving average of $11.17 and a 200-day simple moving average of $11.85. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -554.50 and a beta of 1.43.

Certara (NASDAQ:CERT - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The firm had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The business's revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.10 EPS. On average, sell-side analysts expect that Certara will post 0.28 earnings per share for the current year.

Institutional Investors Weigh In On Certara

Several institutional investors and hedge funds have recently bought and sold shares of the business. AdvisorNet Financial Inc bought a new stake in Certara in the second quarter valued at about $25,000. Versant Capital Management Inc boosted its holdings in Certara by 218.8% during the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after purchasing an additional 1,866 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Certara in the 1st quarter valued at approximately $31,000. Wells Fargo & Company MN grew its stake in shares of Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after purchasing an additional 1,047 shares during the period. Finally, AlphaQuest LLC acquired a new position in shares of Certara in the 1st quarter worth approximately $39,000. Institutional investors own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.